anti-CD3/anti-CD20 bispecific T-cell engager (Biocad)

N/A

Report date: 2026/03/19 16:53:29

Base Information

Drug Nameanti-CD3/anti-CD20 bispecific T-cell engager (Biocad)

Drug Alias Nameanti-CD20/anti-CD3 mAb (Biocad)BCD-105

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionB-lymphocyte antigen CD20 modulatorsT lymphocytes stimulantsT cell surface glycoprotein CD3 modulators +[4]

TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryRussian Federation

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesBIOCAD JSC

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBIOCAD JSC

Active IndicationsN/A

Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A